Independent Safety Data Monitoring Committee Recommends Initiation of Cohort 3 at the Increased Dose of 15 mg/kg in Entrada Therapeutics' ELEVATE-45-201 Study

November 18, 2026

-- ELEVATE-45-201 Cohort 2 (10 mg/kg) enrollment complete with data expected in H1 2027 --

BOSTON, Nov. 18, 2026 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA) today announced that an independent safety Data Monitoring Committee (DMC), per study protocol, has reviewed all available safety and PK data from the eight participants enrolled in Cohort 2 of the double-blind, placebo-controlled, multiple ascending dose (MAD) portion of ELEVATE-45-201. The DMC recommended initiating Cohort 3 at the dose of 15 mg/kg, a dose escalation from 10 mg/kg in Cohort 2 and 5 mg/kg in Cohort 1. ELEVATE-45-201 is a Phase 1/2 MAD clinical study of ENTR-601-45 for the potential treatment of Duchenne muscular dystrophy (DMD) in participants with a confirmed mutation in the *DMD* gene amenable to exon 45 skipping.

"We are pleased with the independent Data Monitoring Committee's recommendation to advance our ELEVATE-45-201 study to Cohort 3 at the elevated dose of 15 mg/kg," said Natarajan Sethuraman, PhD, President of Research and Development at Entrada Therapeutics. "This study progression enables us to further evaluate the safety, pharmacokinetic and pharmacodynamic profile of ENTR-601-45 at both higher doses and exposure levels, where we expect to see meaningfully higher dystrophin production and functional benefits. Importantly, ENTR-601-45 is designed to significantly decrease the burden of treatment on patients and their families by supporting a dosing schedule of just once every six weeks. We look forward to sharing data from Cohort 2 in the first half of 2027, with Cohort 3 to follow."

Patients and Their Care Partners
Patients and their care partners are a critical part of our community, and we are committed to keeping them informed and connected. To receive community updates in real time and read today's update, please visit Community Updates on our corporate website or follow us on Facebook.

About the ELEVATE-45-201 Phase 1/2 Study
ELEVATE-45-201 is a global, two-part, randomized, double-blind, placebo-controlled Phase 1/2 study evaluating the safety, tolerability and effectiveness of ENTR-601-45 in ambulatory participants aged four to 20 living with Duchenne who are exon 45 skipping amenable. The multiple ascending dose (MAD) Part A portion of the study is evaluating the safety, pharmacokinetics, pharmacodynamics and functional parameters of ENTR-601-45 administered intravenously every six weeks to study participants across three cohorts at sites in the U.K. and EU.

About ENTR-601-45
ENTR-601-45 is a proprietary Endosomal Escape Vehicle (EEV™)-conjugated oligonucleotide that has a sequence designed and optimized for people with a confirmed mutation in the *DMD* gene that is amenable to exon 45 skipping, which comprises approximately nine percent of the Duchenne patient population globally. These patients face an aggressive disease course, with a median age at loss of ambulation of between 11 and 14 years among those receiving standard-of-care treatment. ENTR-601-45 is designed to address the underlying cause of Duchenne, facilitating production of functional dystrophin from the endogenous (naturally occurring) *DMD* gene.

About Duchenne Muscular Dystrophy (DMD)
Duchenne muscular dystrophy (DMD) is a rare disease caused by mutations in the *DMD* gene, which encodes the dystrophin protein. These mutations lead to inadequate dystrophin production. Dystrophin is essential to maintaining the structural integrity and function of muscle cells. Lack of functional dystrophin leads to progressive loss of muscle strength, impacting mobility and causing heart or respiratory complications that contribute to high mortality rates. An estimated 41,000 people in the U.S. and Europe are living with DMD. Of those, approximately 11,500 are amenable to exon 44, 45, 50 and 51 skipping.

About Entrada Therapeutics
Entrada Therapeutics is a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of genetic medicines that engage intracellular targets that have long been considered inaccessible. Through proprietary, versatile and modular approaches, Entrada is advancing a robust development portfolio of genetic medicines for the potential treatment of neuromuscular and inherited retinal diseases, among others. The Company's lead oligonucleotide programs are in development for the potential treatment of people living with Duchenne muscular dystrophy who are exon 44, 45, 50 or 51 skipping amenable. Entrada has partnered to develop a clinical-stage program, VX-670, for myotonic dystrophy type 1.

For more information about Entrada, please visit our website, www.entradatx.com, and follow us on LinkedIn.

Forward-Looking Statements
This press release contains express and implied forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained in this press release, including statements regarding Entrada's strategy, future operations, prospects and plans, objectives of management, the validation and differentiation of Entrada's approach and EEV platform and its ability to provide a potential treatment for patients, expectations regarding Entrada's ELEVATE-45-201 study, including the timing of sharing data from Cohort 2 in the first half of 2027, with Cohort 3 to follow, expectations regarding the ELEVATE-45-201 study's elevated dose of 15 mg/kg for Cohort 3, including the ability to enable Entrada to further evaluate the safety, pharmacokinetic and pharmacodynamic profile of ENTR-601-45 at both higher doses and exposure levels and expectations of seeing meaningfully higher dystrophin production and functional benefits, the ability of ENTR-601-45 to significantly decrease the burden of treatment on patients and their families by supporting a dosing schedule of just once every six weeks, the potential for ENTR-601-45 to address the underlying cause of DMD, facilitating production of functional dystrophin from the endogenous (naturally occurring) *DMD* gene, the potential therapeutic benefits of Entrada's EEV product candidates, including the continued development and advancement of

ENTR-601-44, ENTR-601-45, ENTR-601-50, or ENTR-601-51 for the treatment of DMD and the partnered product candidate VX-670 for the potential treatment of DM1, and the ability to continue to expand and develop additional therapeutic programs and modalities, including the potential treatment of neuromuscular and inherited retinal diseases, constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “might,” “objective,” “ongoing,” “plan,” “predict,” “project,” “potential,” “should,” or “would,” or the negative of these terms, or other comparable terminology are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Entrada may not actually achieve the plans, intentions or expectations disclosed in these forward-looking statements, and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in these forward-looking statements as a result of various important factors, including: uncertainties inherent in the identification and development of product candidates, including the conduct of research activities and the initiation and completion of preclinical studies and clinical studies; uncertainties as to the availability and timing of results from preclinical and clinical studies; the timing of and Entrada’s ability to submit and obtain regulatory clearance and initiate clinical studies; whether results from preclinical studies or clinical studies will be predictive of the results of later preclinical studies and clinical studies; whether Entrada’s cash resources will be sufficient to fund the Company’s foreseeable and unforeseeable operating expenses and capital expenditure requirements; as well as the risks and uncertainties identified in Entrada’s filings with the Securities and Exchange Commission (SEC), including the Company’s most recent Form 10-K and in subsequent filings Entrada may make with the SEC. In addition, the forward-looking statements included in this press release represent Entrada’s views as of the date of this press release. Entrada anticipates that subsequent events and developments will cause its views to change. However, while Entrada may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing Entrada’s views as of any date subsequent to the date of this press release.

Investor Contact
Doug Snow
Head of Investor Relations
dsnow@entradatx.com

Patient Advocacy Contact
Sarah Friedhoff
Head of Patient Advocacy
patientadvocacy@entradatx.com

Media Contact
Megan Prock McGrath
CTD Comms, LLC
megan@ctdcomms.com